<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0183">Barriers to achieving a cure for both HIV-1 and HBV infections were discussed and included: 
 <list list-type="simple" id="JVEv5-list-0008">
  <list-item id="JVEv5-li-0029">
   <label>•</label>
   <p id="JVEv5-para-0184">lack of an appropriate animal models for these infections;</p>
  </list-item>
  <list-item id="JVEv5-li-0030">
   <label>•</label>
   <p id="JVEv5-para-0185">absence of biomarkers in the cure field;</p>
  </list-item>
  <list-item id="JVEv5-li-0031">
   <label>•</label>
   <p id="JVEv5-para-0186">host variability and various viral genotypes/sub-genotypes that require identification of the appropriate populations for evaluating therapeutic candidates and ethical considerations arising from testing cure therapies in humans;</p>
  </list-item>
  <list-item id="JVEv5-li-0032">
   <label>•</label>
   <p id="JVEv5-para-0187">barriers between companies, academic institutions, consortia, funding agencies and regulators impede accelerating research towards a cure;</p>
  </list-item>
  <list-item id="JVEv5-li-0033">
   <label>•</label>
   <p id="JVEv5-para-0188">communicating research in terms accessible to a range of stakeholders from those affected to medical practitioners, regulators and the public in general;</p>
  </list-item>
  <list-item id="JVEv5-li-0034">
   <label>•</label>
   <p id="JVEv5-para-0189">the need to engage with pharmaceutical companies to invest in development of research tools (biomarker, models); and</p>
  </list-item>
  <list-item id="JVEv5-li-0035">
   <label>•</label>
   <p id="JVEv5-para-0190">the absence of a roadmap to cure.</p>
  </list-item>
 </list>
</p>
